Skip to main content
Guangdong Hybribio Biotech Co.,Ltd. logo

Guangdong Hybribio Biotech Co.,Ltd. — Investor Relations & Filings

Ticker · 300639 ISIN · CNE100002N51 LEI · 655600IZO2GZ4A2SFO89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,536 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300639

About Guangdong Hybribio Biotech Co.,Ltd.

https://www.hybribio.cn

Guangdong Hybribio Biotech Co.,Ltd. specializes in the research, development, and manufacturing of molecular diagnostic products and integrated laboratory services. The company is recognized for its proprietary flow-through hybridization technology, which serves as the foundation for its extensive range of diagnostic kits. Key product lines include Human Papillomavirus (HPV) genotyping assays for cervical cancer screening, as well as molecular tests for sexually transmitted infections, respiratory diseases, and neonatal genetic screening for conditions such as Thalassemia and G6PD deficiency. Hybribio provides automated nucleic acid extraction systems and real-time PCR platforms to facilitate high-throughput clinical diagnostics. Its solutions are utilized by medical institutions and public health programs to support early disease detection and personalized medicine through advanced molecular analysis.

Recent filings

Filing Released Lang Actions
关于全资子公司取得医疗器械注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement about a wholly owned subsidiary obtaining a medical device registration certificate from the National Medical Products Administration. It contains no financial statements or investor presentation materials, nor does it announce earnings, management changes, dividends, or financing. It is a general regulatory/compliance announcement that does not fit other specific categories, so it falls under the fallback Regulatory Filings category (RNS).
2026-05-21 Chinese
广东信达律师事务所关于公司二〇二五年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from Guangdong Xinda Law Firm regarding the 2025 Annual General Meeting (AGM) of Guangdong Kaipu Biotechnology Co., Ltd. It details the convening and holding of the AGM, the qualifications of attendees, the voting procedures, and the results of the votes on various proposals including the 2025 annual report and other corporate matters. The document is not the annual report itself but a legal opinion on the AGM process and voting results. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of the AGM. The document length is sufficient and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2026-05-19 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2025 Annual General Meeting (AGM) resolutions of Guangdong Kaipu Biotechnology Co., Ltd. It details the meeting convening, attendance, voting procedures, and the voting results on various proposals including the 2025 annual report, profit distribution, remuneration, and audit firm appointment. The document is a formal announcement of the shareholder meeting decisions rather than the full annual report or financial statements. The length is 4244 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-19 Chinese
关于持股5%以上股东减持股份触及1%及5%整数倍暨披露简式权益变动报告书的提示性公告
Major Shareholding Notification Classification · 90% confidence The document is a stock exchange announcement detailing the reduction of a >5% shareholder’s stake, notifying that the shareholding percentage has crossed the 5% threshold and describing the change in holdings. This matches Major Shareholding Notification filings (MRQ).
2026-05-14 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 93% confidence The document is a detailed simplified equity change report (“简式权益变动报告书”) filed by a shareholder disclosing its shareholding changes, including reduction below the 5% threshold. It is not an earnings or interim report, nor merely a publication notice; it specifically notifies a major shareholding change crossing regulatory thresholds. This fits the “Major Shareholding Notification” category.
2026-05-14 Chinese
关于持股5%以上股东权益变动触及1%整数倍的公告
Major Shareholding Notification Classification · 92% confidence The document is a regulatory announcement by Guangdong Kaipu Bio-Tech Co. and its >5% shareholder regarding changes in shareholding that have crossed a 1% threshold. It details the shareholding adjustments and meets the definition of a Major Shareholding Notification (notification of changes in significant share ownership levels crossing thresholds).
2026-05-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.